After stimulation of the TCR with an antibody, fewer CD3É› mutant T cells showed ERK phosphorylation and CD69 upregulation than the wild-type T cells, suggesting the mutant CD3 could not signal as ...
In a study published in Nature Neuroscience, researchers from Tiziana Life Sciences Ltd. and collaborators investigated the potential of nasal delivery of the CD3 foralumab to reduce neuroinflammation ...
The following is a summary of “Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma ...
In 1986, the CD3-specific monoclonal antibody muromonab (Orthoclone OKT3 ... mediator may be viewed as being similar to inherited primary immunodeficiencies and that a deeper understanding ...
CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells.
Accepted for Priority Review Linvoseltamab (GSK) B-cell maturation antigen CD3-targeted bispecific antibody Treatment of adult patients with relapsed/refractory multiple myeloma who have received ...
A nasal spray, referred to as nasal anti-CD3, could be the first FDA-approved treatment for traumatic brain injury, or TBI, that can be easily administered with no serious side effects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback